Fedora Pharmaceuticals Inc. was founded in 2012 and is headquartered in Edmonton, Alberta, Canada. Since its inception, the company has been dedicated to the discovery and development of novel antimicrobial drug candidates with activity against multi-drug resistant pathogens. Fedora’s first product candidate, FPI-1459 (RG6080), is a beta-lactamase inhibitor that was licensed by Roche in January 2015 in an agreement valued at up to $750 million.
Fedora is actively building a pipeline of antibiotic compounds targeting Gram-negative and Gram-positive microbes. Funded in part by a contribution from the National Research Council of Canada’s Industrial Research Assistance Program (NRC-IRAP), Fedora is currently evaluating several compounds with the goal of selecting one or more candidates to advance into preclinical studies in 2017.
Fedora's management and scientific team of staff and collaborators bring a wealth of knowledge and expertise in drug discovery and development to the challenge of antimicrobial drug development. Together, they have led the discovery and development of an extensive list of anti-infectives, many of which are in clinical use today.